Loading...
01/11 16:21
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presents a mixed sentiment. Positive aspects include the potential growth from the BIOTRONIK acquisition and revenue synergies, as well as optimistic guidance for the interventional business. However, concerns arise from increased tax rates, cash flow declines, and tariff impacts. The Q&A section reveals uncertainty in management's responses regarding margin phasing and NewCo's future, which tempers the overall sentiment. Considering these factors, the stock price is likely to remain stable in the short term, leading to a neutral sentiment prediction.
Second Quarter Revenues $780.9 million, an increase of 4.2% year-over-year on a GAAP basis and up 1% on an adjusted constant currency basis. Growth was driven by strength in intra-aortic balloon pumps, partially offset by OEM declines and challenges in UroLift.
Adjusted Earnings Per Share (EPS) $3.73, a 9.1% increase year-over-year. The increase was primarily due to higher adjusted operating income, a lower share count, and a positive benefit of foreign exchange.
Americas Revenues $525.7 million, a 2% increase year-over-year. Growth was driven by intra-aortic balloon pumps, partially offset by OEM declines and challenges in UroLift.
EMEA Revenues $166.2 million, a decrease of 2.1% year-over-year. Decline was due to a tough year-over-year comparison in military orders and challenges in the Anesthesia business.
Asia Revenues $89 million, a 1.2% increase year-over-year. Growth was driven by strength in Southeast Asia, India, and Japan, partially offset by volume-based procurement dynamics in China.
Vascular Access Revenue $185.5 million, a 1.4% increase year-over-year. Growth was led by double-digit growth in PICCs and solid performance in EZ-IO.
Interventional Revenue $170 million, an increase of 19.3% year-over-year. Growth was driven by intra-aortic balloon pumps, catheters, OnControl, complex catheters, and right heart catheters.
Anesthesia Revenue $96.4 million, a decrease of 7.6% year-over-year. Decline was due to a tough comparison in military orders and pressure on airway products.
Surgical Revenue $114 million, a 1.4% increase year-over-year. Growth in the North America surgical business was offset by volume-based procurement in China.
Interventional Urology Revenue $76.4 million, a decrease of 8.3% year-over-year. Decline was due to pressure on UroLift, despite strong double-digit growth for Barrigel.
OEM Revenue $78.7 million, a decrease of 12.4% year-over-year. Decline was due to a lost customer contract and continued customer inventory management.
Other Revenues $59.9 million, an increase of 3.5% year-over-year. Growth was driven by Urology Care, particularly intermittent catheters.
Adjusted Gross Margin 59.7%, a 110 basis point decrease year-over-year. Decline was due to cost inflation, increased logistics and distribution costs, and unfavorable product mix, partially offset by foreign currency exchange rates.
Adjusted Operating Margin 26.9%, a 20 basis point increase year-over-year. Improvement was due to prudent operating expense control and a positive benefit from foreign exchange rates.
Adjusted Net Interest Expense $19.9 million, a slight increase from $19.4 million in the prior period. Increase was due to higher average debt outstanding, partially offset by lower interest rates on floating rate debt.
Adjusted Tax Rate 13.1%, compared to 12.3% in the prior year period. Increase was due to additional costs arising from the enactment of Pillar 2 tax reform.
Cash Flow from Operations (First 6 Months) $81.2 million, a decrease of $123.3 million year-over-year. Decline was due to unfavorable changes in working capital, payments for tariffs, separation costs, and acquisition-related expenses.
Cash, Cash Equivalents, and Restricted Cash Equivalents $283.9 million at the end of the second quarter, compared to $327.7 million as of year-end 2024. Decline was due to acquisition-related expenses and other factors.
Vascular Intervention Business Acquisition: Teleflex completed the acquisition of BIOTRONIK's Vascular Intervention business for EUR 704 million. The acquired portfolio includes drug-coated balloons, drug-eluting stents, and other vascular devices. This acquisition is expected to generate $204 million in revenue in the second half of 2025 and $800 million annually starting in 2026.
Freesolve Technology: Teleflex plans to expand clinical trials for Freesolve, a sirolimus-eluting resorbable metallic scaffold technology. The European BioMag 2 study is ahead of schedule, and a U.S. pivotal study will begin soon.
Titan SGS Stapler: Clinical data supports the Titan SGS stapler's effectiveness in reducing GERD and improving surgical outcomes for laparoscopic sleeve gastrectomy patients.
Geographic Revenue Performance: Americas revenue grew 2% year-over-year, driven by intra-aortic balloon pumps. EMEA revenue declined 2.1%, while Asia revenue increased 1.2%, with growth in Southeast Asia, India, and Japan offset by challenges in China.
Interventional Business Growth: Interventional revenue grew 19.3% year-over-year, driven by intra-aortic balloon pumps, catheters, and other products.
Operational Efficiencies: Adjusted operating margin increased to 26.9% due to cost control and favorable foreign exchange rates. Adjusted gross margin was 59.7%, impacted by inflation and product mix.
Tariff Mitigation: Teleflex reduced expected tariff impact for 2025 to $29 million from $55 million by optimizing supply chains and increasing USMCA-compliant products.
Separation of Teleflex: Teleflex is progressing with its separation plan announced in February, aiming to streamline operations and maximize shareholder value. A potential sale of NewCo is also being evaluated.
Capital Allocation Strategy: Proceeds from a potential sale of NewCo may be used to reduce debt and return capital to shareholders.
Revenue Challenges in EMEA: EMEA revenues decreased 2.1% year-over-year, driven by softness in the Anesthesia business and tough year-over-year comparisons in military orders.
China Market Dynamics: Revenue growth in Asia was partially offset by volume-based procurement dynamics in China, though sequential improvement was noted.
UroLift Performance: Interventional Urology revenue decreased 8.3% year-over-year, with continued pressure on UroLift despite strong growth in Barrigel.
OEM Revenue Decline: OEM revenue decreased 12.4% year-over-year due to a lost customer contract and continued customer inventory management.
Cost Inflation: Adjusted gross margin decreased due to cost inflation in labor, raw materials, logistics, and distribution.
Tariff Impact: Tariffs are expected to impact 2025 financials by approximately $29 million, though this is a reduction from prior estimates.
Integration Costs for Vascular Intervention Acquisition: Incremental expenses associated with the acquisition of the Vascular Intervention business are expected to impact adjusted operating margin.
Debt and Interest Expense: Net interest expense increased due to higher average debt outstanding, primarily from financing the Vascular Intervention acquisition.
Regulatory and Taxation Changes: The adjusted tax rate increased due to additional costs arising from the enactment of Pillar 2 tax reform.
Revenue Growth: Teleflex expects total constant currency growth for 2025 to be in the range of 7.7% to 8.7%, revised upward from the prior guidance of 1% to 2%. This includes an estimated $204 million in revenue contribution from the Vascular Intervention acquisition in the second half of the year.
Foreign Exchange Impact: The company anticipates a positive impact from foreign exchange of $26 million in 2025, representing an approximately 85 basis point tailwind to GAAP revenue growth.
GAAP Revenue Growth: GAAP revenue growth for 2025 is projected to be in the range of 9% to 10%, implying a dollar range of $3.322 billion to $3.352 billion.
Tariff Impact: The expected impact from tariffs in 2025 has been reduced to approximately $29 million or $0.55 per share, down from the previous outlook of $55 million or $1.05 per share. This reduction is attributed to changes in tariff rates and mitigation efforts.
Adjusted Gross Margin: The company has increased its 2025 adjusted gross margin guidance to a range of 58.75% to 59.5%, reflecting a 50 basis point increase at both the low and high ends of the range.
Adjusted Operating Margin: Adjusted operating margin for 2025 is expected to be in the range of 24.5% to 25%, reflecting a 10 basis point reduction at the low end of the range compared to prior guidance.
Net Interest Expense: Net interest expense for 2025 is now expected to be approximately $95 million, up from $75 million previously, primarily due to financing associated with the Vascular Intervention acquisition.
Tax Rate: The adjusted tax rate for 2025 is now expected to be 13.25%, revised from the previous expectation of 13.5%.
Adjusted Earnings Per Share: Adjusted EPS for 2025 is projected to be in the range of $13.90 to $14.30, reflecting a $0.70 increase at both the low and high ends of the range. This includes a $0.50 benefit from a lower-than-expected tariff impact.
Third Quarter Revenue Outlook: For Q3 2025, adjusted constant currency growth is expected to be in the range of 15% to 16.5%, including $99 million in revenue from the Vascular Intervention acquisition.
Shareholder Return Plan: Should a sale be consummated, we currently intend to utilize proceeds to balance paydown of debt and return capital to shareholders.
The earnings call highlights several positive factors: increased revenue growth guidance, improved adjusted gross margins, and strong performance in the Vascular Intervention business. The Q&A session further supports this with positive insights on market share growth and successful integration of acquisitions. Although cash flow from operations decreased, the overall financial outlook and strategic plans, including a focus on maximizing shareholder value through a potential sale, suggest a positive sentiment. The upward revision of guidance and strong market performance indicate a likely positive stock price movement in the short term.
The earnings call reveals several negative indicators: declining unit and dollar volumes, reduced market share, and underperformance of past loan vintages. Although there is some positive news with the 2025 vintage exceeding expectations and share repurchases, the overall sentiment is dampened by intense competition, tariffs, and rising costs. The Q&A section highlights concerns about unclear management responses and potential negative economic returns, further contributing to a negative outlook.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
